Drug Trial Radar · NCT01642888
A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI
Last checked: Nov 19, 2026Latest source record: Apr 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,190
Actual
Start
Sep 2012
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Statens Serum InstitutAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 28 days, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Tuberculosis (TB) continues to be one of the most serious bacterial infections worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB. The new skin test is named C-Tb. Like the current tuberculin skin test, PPD, the C-Tb test is injected just under the skin and will, when positive, show redness and/or swelling at the injection site while a negative test will leave no reactions. The investigators hope that this new C-Tb skin test will be more precise (specific) than the PPD test, as the PPD test e.g. may show a reaction if the person tested is BCG vaccinated. The aim of this trial is to test the C-Tb skin test in volunteers suspected of having TB disease. With focus on age, HIV status and CD4 count the following analyses are done (in an overall perspective): * To compare the C-Tb test to a blood test, the QuantiFERON test. * To compare the C-Tb test to the PPD test that is currently being used. * To assess the safety of the C-Tb test.
Conditions
- Tuberculosis
Interventions
C-TbBiological
The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
2 T.U. Tuberculin PPD RT 23 SSIBiological
The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the diagnostic performance of C-Tb in relation to age, HIV and CD4 countsTime frame: Onset between the injections and 28 days after the injections
- To evaluate the clinical safety of C-Tb, with emphasis on children and HIV positive participantsTime frame: Onset between the injections and 28 days after the injections
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Primecure Medicentre, Mercantile Hospital
Port Elizabeth, Eastern Cape, South Africa
Worthwhile Clinical Trials, Lakeview Hospital
Benoni, Gauteng, South Africa
Synnyside Medi-Clinic
Pretoria, Gauteng, South Africa
Synexus Stanza Bopape Clinic
Pretoria, Gauteng, South Africa
Setshaba Research Centre
Pretoria, Gauteng, South Africa
M2 Karl Bremer Hospital
Bellville, Cape Town, Western Cape, South Africa
Tiervlei Trial Centre, Karl Bremer Hospital
Bellville, Cape Town, Western Cape, South Africa
UCT Lung Institute, Groote Schuur Hospital
Cape Town, Western Cape, South Africa
Be Part Yoluntu Centre
Paarl, Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.